Navigation Links
Iomai Announces Year-End 2007 Financial Results and Business Progress
Date:3/6/2008

d number of shares outstanding as a result of our $30.2 million private placement completed on March 2, 2007. For the fourth quarter of 2007, Iomai's net loss was $6.2 million, or $0.24 loss per share, compared to a net loss in the fourth quarter of 2006 of $9.9 million, or $0.53 loss per share. As of Dec. 31, 2007, Iomai had common stock outstanding of 25,588,673 shares.

The Company reported revenues of $10.7 million for the year ended Dec. 31, 2007, compared to $1.5 million in the year ended Dec. 31, 2006. The increase in revenue in 2007 was principally from the reimbursement of expenses incurred under the DHHS contract. Iomai reported revenues of approximately $3.3 million in the fourth quarter of 2007, compared to approximately $40,000 in the fourth quarter of 2006.

Total operating expenses were $39.8 million in 2007, compared to operating expenses of $33.9 million in 2006. The increase in operating expenses was primarily due to five major factors associated with supporting our development programs: (1) higher payroll and stock compensation costs associated with a 28% increase in full-time employee equivalents, (2) higher facility costs associated with leasing additional space, (3) increased animal study costs associated with work performed under our DHHS contract, (4) higher contract manufacturing costs associated with procuring and finishing the pandemic flu vaccine for the clinical trial under the DHHS contract, and (5) higher consulting costs associated with market studies for our product candidates. These increased costs were partially offset by lower development costs for our skin preparation system.

Total operating costs for the fourth quarter of 2007 were $9.6 million as compared to $10.1 million for the fourth quarter of 2006. The decrease in operating expenses was primarily due to decreased in year-to-year clinical trial costs for Iomai's needle-free travelers' diarrhea vaccine and decreased contract manufacturing expenses.


'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
2. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
3. Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13
4. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
5. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
6. Dragon announces new product launch; increase in annual production output capacity
7. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
8. China Yingxia International Announces Q4 and FY 2007 Estimates
9. Bristol-Myers Squibb Announces Dividend
10. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
11. Maxygen Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
(Date:8/27/2014)... After the boom of the energy drink ... craze is going to be the stress relief drinks. ... Stress Relief energy pattern which can be applied to ... beverage, including minerals, herbs and liquids. Stress Relief generates ... into rapid recovery and helping to adapt more quickly. ...
(Date:8/27/2014)... Hunting Valley, Ohio (PRWEB) August 27, 2014 ... five students from Cleveland's University School ... at Case Western Reserve University’s School of ... program provides students with an unparalleled professional experience ... with the School of Medicine faculty and students ...
(Date:8/26/2014)... 26, 2014 An analysis by Replikins, Ltd. ... Mers CoV virus strains has revealed extensive ... 2012.  This conservation and sharing of specific Replikin gene ... Blocker-Vaccine™ candidate, as it did for the H5N1 influenza ... which have been found to be effective (1,2). ...
Breaking Biology Technology:Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... Still Earn D,s or F,s on ... Legislation Report Card, WASHINGTON, March 11 For the ... laws that,require insurance providers to cover the cost of colon cancer screening,tests, according ... groups. The enactment of new coverage laws in five states,during 2007 also increased ...
... 11 Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ... PBI,s senior executive management team as Vice President,of ... years of experience in,sales and sales management at ... will oversee PBI,s seven US-based, regional sales directors ...
... an Interferon-Beta Therapy, According to a New Report from Decision ... ... Mass., March 11 Decision Resources, one of the,world,s leading research ... Pharmaceutical,s Copaxone has the,greatest patient share among first- and second-line therapies, ...
Cached Biology Technology:Colon Cancer Screening Laws Now Cover Half of U.S. Population 2Colon Cancer Screening Laws Now Cover Half of U.S. Population 3Colon Cancer Screening Laws Now Cover Half of U.S. Population 4Colon Cancer Screening Laws Now Cover Half of U.S. Population 5Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 2Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 3Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 4Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html ... to assess individuals on the basis of their ... and identification of both physiological traits such as ...
(Date:8/27/2014)... easier when it only requires nerve cells to rearrange ... have to generate new patterns, a study of monkeys ... learn through recordings of electrical activity of brain cell ... Institutes of Health. , "We looked into the brain ... think outside the box," said Aaron Batista, Ph.D., an ...
(Date:8/27/2014)... LAKE CITY, Aug. 27, 2014 University of Utah ... his native Turkey, has won that nation,s highest science ... of Science. , Sekercioglu is among five researchers picked ... and Technical Research Council of Turkey. Three researchers won ... won the Special Award, which is equivalent to the ...
Breaking Biology News(10 mins):Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5Scientists plug into a learning brain 2Scientists plug into a learning brain 3University of Utah biologist wins Turkey's top science prize 2
... Ill., Nov. 15 Corporate Safe Specialists (CSS),announces ... The,Company has hired Randy Biela, a software engineer, ... http://www.newscom.com/cgi-bin/prnh/20070119/CGF030LOGO ) Ed McGunn, President and CEO ... department of five full-time employees led by myself. ...
... dogs and humans display many of the same characteristics, ... breast cancer progression and prevention for people and pets, ... Veterinary Medicine. A group of scientists including Sulma ... considered to carry risk for developing breast cancer in ...
... do immobile organisms like plants cope when faced with ... question in light of new environmental conditions brought on ... study, published in the Nov. 16 issue of the ... setting as their maternal plant performed almost 3 times ...
Cached Biology News:Corporate Safe Specialists Announces Additions to R&D Team 2Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 2Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 3Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 4Evolutionary biology research on plant shows significance of maternal effects 2
... the efficient enrichment of functional endoplasmic ... cell culture. The isolated ER are ... metabolic pathway analysis. Metabolic abnornalities of ... children, cystic fibrosis and many more ...
Plasmid expressing PLAP reporter gene....
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: